XORTX Therapeutics is a pre-revenue, late clinical-stage Canadian biotech developing drugs to treat diseases driven by elevated uric acid and abnormal purine metabolism. The company's core technology is XORLO, a proprietary oral formulation of oxypurinol — the active metabolite of allopurinol, the most widely used gout drug — which XORTX argues delivers better bioavailability than non-formulated oxypurinol. XORTX has four pipeline programs, all based on inhibiting xanthine oxidase, the enzyme that produces uric acid. The lead program, XRx-026, targets gout patients intolerant to allopurinol, an estimated 120,000–150,000 U.S. patients; XORTX is pursuing FDA approval via the 505(b)(2) pathway and estimates the program is roughly 12 months from an NDA filing. The second program, XRx-008, targets autosomal dominant polycystic kidney disease (ADPKD), a rare condition where the only approved therapy carries a liver toxicity warning; this program has FDA Orphan Drug Designation, which would provide 7 years of U.S. market exclusivity if approved. Two earlier-stage programs target acute kidney injury in hospitalized respiratory virus patients (XRx-101) and type 2 diabetic nephropathy (XRx-225). XORTX has no approved products and funds operations entirely through equity issuances. If products are approved, XORTX intends to commercialize independently and through third-party partnerships, relying on contract manufacturers for drug production.